Risk factors for sustained virological non-suppression among children and adolescents living with HIV in Zimbabwe and Malawi: a secondary data analysis
-
Published:2022-06-11
Issue:1
Volume:22
Page:
-
ISSN:1471-2431
-
Container-title:BMC Pediatrics
-
language:en
-
Short-container-title:BMC Pediatr
Author:
Jackson Christi,Rehman Andrea M.,McHugh Grace,Gonzalez-Martinez Carmen,Ngwira Lucky G.,Bandason Tsitsi,Mujuru Hilda,Odland Jon O.,Corbett Elizabeth L.,Ferrand Rashida A.,Simms Victoria
Abstract
AbstractBackgroundWe investigated risk factors for sustained virological non-suppression (viral load ≥ 1000 copies/ml on two tests 48 weeks apart) among children and adolescents accessing HIV care in public sector clinics in Harare, Zimbabwe and Blantyre, Malawi.MethodsParticipants were enrolled between 2016 and 2019, were aged 6–19 years, living with HIV, had chronic lung disease (FEV z-score < -1) and had taken antiretroviral therapy (ART) for at least six months. We used multivariate logistic regression to identify risk factors for virological non-suppression after 48 weeks, among participants who were non-suppressed at enrolment.ResultsAt enrolment 258 participants (64.6%) were on first-line ART and 152/347 (43.8%) had virological non-suppression. After 48 weeks 114/313 (36.4%) were non-suppressed. Participants non-suppressed at baseline had almost ten times higher odds of non-suppression at follow-up (OR = 9.9, 95%CI 5.3–18.4,p < 0.001). Of those who were non-suppressed at enrolment, 87/136 (64.0%) were still non-suppressed at 48 weeks. Among this group non-suppression at 48 weeks was associated with not switching ART regimen (adjusted OR = 5.55; 95%CI 1.41–21.83);p = 0.014) and with older age. Twelve participants switched regimen in Zimbabwe and none in Malawi.ConclusionsViral non-suppression was high among this group and many with high viral load were not switched to a new regimen, resulting in continued non-suppression after 48 weeks. Further research could determine whether improved adherence counselling and training clinicians on regimen switches can improve viral suppression rates in this population.Trial registrationSecondary cohort analysis of data from BREATHE trial (Clinicaltrials.govNCT02426112).
Funder
Medical Research Council
Foreign, Commonwealth and Development Office
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference24 articles.
1. Ministry of Health and Child Care. Harare: 2019. Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2015–2016. Final Report.
2. Ministry of Health and Child Care. Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare: Zimbabwe Ministry of Health and Child Care; 2016
3. Malawi Ministry of Health. Malawi guidelines for clinical management of HIV in children and adults. 3rd ed. Lilongwe: Malawi Ministry of Health; 2016.
4. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organisation; 2016
5. Madec Y, Leroy S, Rey-Cuille MA, Huber F, Calmy A. Persistent difficulties in switching to second-line ART in sub-saharan Africa–a systematic review and meta-analysis. PLoS One. 2013;8(12):e82724.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献